Kringle Pharma, Inc. (TYO:4884)

Market Cap	2.79B -48.8%
Revenue (ttm)	73.00M +1.4%
Net Income	-920.00M
EPS	-130.47
Shares Out	7.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,000
Open	373.00
Previous Close	377.00
Day's Range	346.00 - 373.00
52-Week Range	347.00 - 1,125.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	May 11, 2026

About Kringle Pharma

Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4884

Financial Performance

In fiscal year 2025, Kringle Pharma's revenue was 72.00 million, a decrease of -10.00% compared to the previous year's 80.00 million. Losses were -916.00 million, 21.2% more than in 2024.